Deinove Overview

  • Founded
  • 2006
Founded
  • Status
  • Public
  • Employees
  • 57
Employees
  • Stock Symbol
  • ALDEI
Stock Symbol
  • Investments
  • 2
  • Share Price
  • $0.79
  • (As of Friday Closing)

Deinove General Information

Description

Deinove SA is a biotechnology company engaged in the development of technologies and molecules for the health, nutrition and cosmetics industries. It is developing in two areas of activity, New-generation anti-infective ANTIBIOTICS which involves the search for novel anti-infective molecules and the development of new generations of drugs capable of responding to the challenges of antibiotic resistance; and BIOACTIVES, natural active ingredients discovers, develops and produces bioactives, active ingredients of natural origin from its bacterial biodiversity bank, to invent the new generation of sustainable cosmetics and intends to quickly bring its know-how and its products to other fields, such as nutrition and health.

Contact Information

Website
www.deinove.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
PAR
Primary Office
  • ZAC Euromédecine II, Cap Sigma
  • 1682 Rue de la Valsière, Grabels
  • 34790 Montpellier
  • France
+33 04 00 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Deinove Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.79 $0.80 $0.54 - $1.51 $22.3M 28.1M 162K -$0.34

Deinove Financials Summary

In Thousands,
USD
TTM 31-Dec-2020 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 19,831 19,831 11,795 14,629
Revenue 368 368 182 46
EBITDA (8,156) (8,156) (12,327) (10,492)
Net Income (8,321) (8,321) (11,471) (10,322)
Total Assets 11,572 11,572 11,634 19,011
Total Debt 4,005 4,005 1,483 392
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Deinove Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Deinove‘s full profile, request access.

Request a free trial

Deinove Executive Team (11)

Name Title Board Seat Contact Info
Alexis Rideau Chief Executive Officer
Julien Coste Director, Finance
Miroslav Radman Ph.D Co-Founder
Charles Woler Ph.D Chairman
Philippe Pouletty MD Co-Founder & Board Member
You’re viewing 5 of 11 executive team members. Get the full list »

Deinove Board Members (12)

Name Representing Role Since
Charles Woler Ph.D Deinove Chairman 000 0000
Emmanuel Petiot Deinove Board Member 000 0000
Michael Carlos Self Board Member 000 0000
Philippe Pouletty MD Self Co-Founder & Board Member 000 0000
You’re viewing 4 of 12 board members. Get the full list »

Deinove Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Deinove Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 23-May-2018 000000000000000000 Biotechnology
Deinobiotics 04-Jan-2017 Merger/Acquisition Drug Delivery 00000000 000000
To view Deinove’s complete acquisitions history, request access »